Pomalidomide Clinical Trials

32 actively recruiting trials across 13 locations

Also known as: 4-Aminothalidomide, Actimid, Anyve, CC-4047, Imnovid, Imnovid, Pomalyst®, Induction phase, Pom, Pomalyst, Pomalyst, Imnovid, Pomalyst®, pom

Filter by location:

Other9 trials

A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients

Phase 3

A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)

Phase 3

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

Phase 1

Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis

Phase 2

Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study

N/A

Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

Phase 2

Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma

N/A

Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients

N/A

Birmingham, Alabama4 trials

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

University of Alabama At Birmingham Hospital

Phase 1/2

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

University of Alabama at Birmingham

Phase 3

Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

The University of Alabama at Birmingham

Phase 2

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

University of Alabama at Birmingham - Main /ID# 261434

Phase 3

Boston, Massachusetts3 trials

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Massachusetts General Hospital

Phase 2

Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma

Massachusetts General Hospital

Phase 2

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Boston Medical Center

Phase 1/2

Gilbert, Arizona2 trials

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

Banner MD Anderson Cancer Center

Phase 3

Selinexor and Backbone Treatments of Multiple Myeloma Patients

Banner MD Anderson Cancer Center

Phase 1/2

Clovis, California2 trials

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

UCSF Fresno

Phase 3

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

Clovis Community Medical Center

Phase 3

Los Angeles, California2 trials

A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

University of Southern California /ID# 272414

Phase 1/2

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

University of California Los Angeles (UCLA)

Phase 3

Atlanta, Georgia2 trials

Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma

Emory University/Winship Cancer Institute

Phase 2

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Emory Winship Cancer Institute

Phase 1/2

Bethesda, Maryland2 trials

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

National Institutes of Health Clinical Center

Phase 1

Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

National Institutes of Health Clinical Center

Phase 1

Mobile, Alabama1 trial

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Infirmary Cancer Care

Phase 3

Duarte, California1 trial

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

City of Hope Medical Center

Phase 2

La Jolla, California1 trial

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Scripps Clinic Torrey Pines

Phase 1

Los Alamitos, California1 trial

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Cancer and Blood Specialty Clinic

Phase 3

Miami, Florida1 trial

A Study of Daratumumab

University of Miami Sylvester Cancer Center

Phase 3

Chicago, Illinois1 trial

Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

University of Chicago Medicine Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.